Article
The MUSCLE-GLP1-CKD study: design and rationale of a prospective real-world cohort evaluating muscle health during GLP-1 receptor agonist therapy in chronic kidney disease and type 2 diabetes
2026-07-23
Abstract excerpt
<title>Abstract</title> <p> <bold>Background</bold> Sarcopenia and impaired physical function are clinically relevant complications of chronic kidney disease (CKD). Patients with CKD and type 2 diabetes mellitus (T2DM) are particularly vulnerable to muscle impairment because of insulin resistance, inflammation, obesity, nutritional abnormalities, multimorbidity and reduced physical activity. Glucagon-like pepti...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a5ef2ba9-0d71-55aa-a9d3-cbcfc37ac11f
- DOI
- 10.21203/rs.3.rs-10372706/v1
